6CM
CAMP icon

683 Capital Management’s CAMP4 Therapeutics CAMP Stock Holding History

683 Capital Management’s Portfolio CAMP Stock Details CAMP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-108,000
Closed -$476K – 170
2026
Q1 		$476K Sell
108,000
-18,363
-15% -$87.2K 0.02% 186
2025
Q4 		$775K Buy
+126,363
New +$538K 0.03% 162

Other funds holding CAMP

JT
Jupiter Topco New York $245B AUM
5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
ACM
AH Capital Management Menlo Park, California $14.2B AUM 20.01% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

683 Capital Management's CAMP Position: Q2 2026 in Review

683 Capital Management sold out of CAMP4 Therapeutics (CAMP) in Q2 2026, closing a stake of 108,000 shares — an estimated $476K sold.

683 Capital Management first reported a position in CAMP in Q4 2025 and held it in 2 quarters. The position peaked at $775K in Q4 2025. 61 funds tracked by Wall St. Rank hold CAMP as of Q2 2026.

  • 683 Capital Management reported no remaining CAMP4 Therapeutics position as of Q2 2026 after selling out during the quarter.
  • 683 Capital Management sold 108,000 CAMP4 Therapeutics shares in Q2 2026, an estimated $476K.
  • 683 Capital Management first reported a position in CAMP4 Therapeutics in Q4 2025 and held it in 2 quarters.
  • 683 Capital Management's CAMP4 Therapeutics position peaked at $775K in Q4 2025.
  • 61 funds tracked by Wall St. Rank held CAMP4 Therapeutics as of Q2 2026.

Based on 683 Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.